The use of desmoteplase (bat saliva) in the treatment of ischaemia

Bibliography

• Ouriel K. A history of thrombolytic therapy. J Endovasc Ther 2004;11(Suppl 2):II128-33
   PubMedGoogle Scholar
• Actilyse, Summary of Product Characteristics. Available from: http://www.medicines.org.uk/emc/medicine/308#INDICATIONShttp://www.medicines.org.uk/emc/medicine/308 - INDICATIONS
   Google Scholar
• Available from: http://www.eso-stroke.org/pdf/ESO_Guideline_Update_Jan_2009.pdfhttp://www.eso-stroke.org/pdf/ESO_Guideline_Update_Jan_2009.pdf
   Google Scholar
• The National Institute of Neurological Disorders and Stroke (NINDS) rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Bluhmki E, Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29
   PubMed Web of Science ®Google Scholar
• Arnold AE, Brower RW, Collen D, Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA. J Am Coll Cardiol 1989;14(3):581-8
   PubMed Web of Science ®Google Scholar
• Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 2010;38(3):376-85
   PubMed Web of Science ®Google Scholar
• Dafer RM, Biller J. Desmoteplase in the treatment of acute ischemic stroke. Expert Rev Neurother 2007;7:333-7
   PubMed Web of Science ®Google Scholar
• Medcalf RL. Desmoteplase: discovery, insights and opportunities for ischaemic stroke. Br J Pharmacol 2012;165(1):75-89
   PubMed Web of Science ®Google Scholar
• Mazighi M, Meseguer E, Labreuche J, Amarenco P. Bridging therapy in acute ischemic stroke: a systematic review and meta-analysis. Stroke 2012;43(5):1302-8
   PubMed Web of Science ®Google Scholar
• Available from: http://www.ninds.nih.gov/disorders/clinical_trials/NCT00359424.htm
   Google Scholar
• Ciccone A, Valvassori L, Ponzio M, Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial. J Neurointerv Surg 2010;2(1):74-9
   PubMed Web of Science ®Google Scholar
• Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01062698?term=THRACE&rank=1http://www.clinicaltrials.gov/ct2/show/NCT01062698?term=THRACE&rank=1
   Google Scholar
• Ma H, Parsons MW, Christensen S, A multicenter, randomized, double-blinded, placebo-controlled Phase III study to investigate Extending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke 2012;7(1):74-80
   PubMed Web of Science ®Google Scholar
• Haley EC Jr, Thompson JL, Grotta JC, Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke 2010;41(4):707-11
   PubMed Web of Science ®Google Scholar
• Parsons M, Spratt N, Bivard A, A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012;366(12):1099-107
   PubMed Web of Science ®Google Scholar
• Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- (ATTEST). Available from: http://clinicaltrials.gov/ct2/show/NCT01472926?term=stroke+AND+thrombolysis&rank=11
   Google Scholar
• A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients. Available from: http://clinicaltrials.gov/ct2/show/NCT01014975?term=stroke+AND+thrombolysis&rank=41http://clinicaltrials.gov/ct2/show/NCT01014975?term=stroke+AND+thrombolysis&rank=41
   Google Scholar
• Gardell SJ, Duong LT, Diehl RE, Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem 1989;264(30):17947-52
   PubMed Web of Science ®Google Scholar
• Gardell SJ, Hare TR, Bergum PW, Vampire bat salivary plasminogen activator is quiescent in human plasma in the absence of fibrin unlike human tissue plasminogen activator. Blood 1990;76(12):2560-4
   PubMed Web of Science ®Google Scholar
• Bringmann P, Gruber D, Liese A, Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995;270(43):25596-603
   PubMed Web of Science ®Google Scholar
• Kratzschmar J, Haendler B, Langer G, The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus, cloning and expression. Gene 1991;105:229-37
   PubMed Web of Science ®Google Scholar
• Schleuning WD, Alagon A, Boidol W, Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): unique fibrin specificity. Ann NY Acad Sci 1992;667:395-403
   PubMed Web of Science ®Google Scholar
• Lopez-Atalaya JP, Roussel BD, Ali C, Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects. Stroke 2007;38(3):1036-43
   PubMed Web of Science ®Google Scholar
• Liberatore GT, Samson A, Bladin C, Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003;34(2):537-43
   PubMed Web of Science ®Google Scholar
• Benchenane K, Berezowski V, Fernandez-Monreal M, Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process. Stroke 2005;36(5):1065-70
   PubMedGoogle Scholar
• Witt W, Maass B, Baldus B, Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalisation by intravenous bolus administration. Circulation 1994;90(1):421-6
   PubMed Web of Science ®Google Scholar
• Witt W, Baldus B, Bringmann P, Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 1992;79(5):1213-17
   PubMed Web of Science ®Google Scholar
• Schleuning WD. Vampire bat plasminogen activator DSPA-Alfa-1 (Desmoteplase): a thrombolytic drug optimized by natural selection. Hemostasis 2001;31:118-22
   PubMedGoogle Scholar
• Tebbe U, Bramlage P, Graf A, Desmoteplase in acute massive pulmonary thromboembolism. Thromb Haemost 2009;101:557-62
   PubMed Web of Science ®Google Scholar
• Hacke W, Albers G, Al-Rawi Y, The desmoteplase in acute ischemic stroke trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36(1):66-73
   PubMed Web of Science ®Google Scholar
• Furlan AJ, Eyding D, Albers GW, Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37(5):1227-31
   PubMed Web of Science ®Google Scholar
• Hacke W, Furlan AJ, Al-Rawi Y, Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8(2):141-50
   PubMed Web of Science ®Google Scholar
• Soehngen W, Petersen KU, Soehngen M. Bat plasminogen activator: desmoteplase – from bat to bench to bedside of stroke victims. In: Kini RM, editor. Toxins and haemostasis. Springer Science+Business Media B.V; Dordrecht, Heidelberg, London and New York; 2010. p. 393-407
   Google Scholar
• Fiebach JB, Al-Rawi Y, Wintermark M, Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase. Stroke 2012;43(6):1561-6
   PubMed Web of Science ®Google Scholar
• The IST-3 Collaborative Group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012;379(9834):2352-63
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-3). Available from: http://clinicaltrials.gov/ct2/show/NCT00790920/http://clinicaltrials.gov/ct2/show/NCT00790920/
   Google Scholar
• Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4). Available from: http://clinicaltrials.gov/ct2/show/NCT00856661/http://clinicaltrials.gov/ct2/show/NCT00856661/
   Google Scholar
• Available from: http://clinicaltrials.gov/ct2/show/NCT01104467?term=DIAS-J&rank=1
   Google Scholar
• Paciaroni M, Medeiros E, Bogousslavsky J. Desmoteplase. Expert Opin Biol Ther 2009;9(6):773-8
   PubMed Web of Science ®Google Scholar
• von Kummer R, Albers GW, Mori E; DIAS Steering Committees. The desmoteplase in acute ischemic stroke (DIAS) clinical trial program. Int J Stroke 2012;7(7):589-96
   PubMed Web of Science ®Google Scholar
• Mishra NK, Albers GW, Davis SM, Mismatch-based delayed thrombolysis: a meta-analysis. Stroke 2010;41(1):e25-33
   PubMed Web of Science ®Google Scholar